Evidence map›Paper›PMID 24315189›Full record

ArticleBioorganic & medicinal chemistry2014

Synthesis of 3-(3-aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazines that have antibacterial activity and also inhibit inorganic pyrophosphatase.

Wei Lv, Biplab Banerjee, Katrina L Molland, Mohamed N Seleem, Adil Ghafoor, Maha I Hamed, Baojie Wan, Scott G Franzblau, Andrew D Mesecar, Mark Cushman

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Crystal structure of an inorganic pyrophosphatase from Chlamydia trachomatis D/UW-3/Cx.Acta crystallographica. Section F, Structural biology communications · 2022
    Article
  5. Article
  6. Article
  7. Chemical Exchange Saturation Transfer (CEST) Agents: Quantum Chemistry and MRI.Chemistry (Weinheim an der Bergstrasse, Germany) · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Wei LvDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy and The Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, United States.
Biplab BanerjeeDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy and The Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, United States.
Katrina L MollandDepartment of Biological Sciences and The Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, United States.
Mohamed N SeleemDepartment of Comparative Pathobiology, Purdue University College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, United States.
Adil GhafoorDepartment of Comparative Pathobiology, Purdue University College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, United States.
Maha I HamedDepartment of Comparative Pathobiology, Purdue University College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, United States.
Baojie WanInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, United States.
Scott G FranzblauInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, United States.
Andrew D MesecarDepartment of Biological Sciences and The Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, United States.
Mark CushmanDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy and The Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, United States. Electronic address: cushman@purdue.edu.
Purdue University West Lafayette · USCenter for Cancer Research · USUniversity of Illinois Chicago · US

Funding

Novel antiobiotic development for biodefenseU01AI077949 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI JOHNSON, MICHAEL E. · 2009 to 2010
$4.0M
NIAID NIH HHS U01 AI077949NIAID NIH HHS UO1AI077949
6 · The paper itself

Abstract

Inorganic pyrophosphatases are potential targets for the development of novel antibacterial agents. A pyrophosphatase-coupled high-throughput screening assay intended to detect o-succinyl benzoic acid coenzyme A (OSB CoA) synthetase inhibitors led to the unexpected discovery of a new series of novel inorganic pyrophosphatase inhibitors. Lead optimization studies resulted in a series of 3-(3-aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazine derivatives that were prepared by an efficient synthetic pathway. One of the tetracyclic triazine analogues 22h displayed promising antibiotic activity against a wide variety of drug-resistant Staphylococcus aureus strains, as well as activity versus Mycobacterium tuberculosis and Bacillus anthracis, at a concentration that was not cytotoxic to mammalian cells.

Indexed as

Anti-Bacterial AgentsHigh-Throughput Screening AssaysInorganic PyrophosphataseMycobacterium tuberculosisStaphylococcus aureusStructure-Activity RelationshipTriazines1,2,4-triazineAnti-Bacterial AgentsInorganic PyrophosphataseTriazines3-(3-Aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazineAntibacterial agentsInhibitorsInorganic pyrophosphatase

Identifiers

PMID24315189
PMCPMC3914758
OpenAlexW2084767468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.